QL2302
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 25, 2025
Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma
(clinicaltrials.gov)
- P3 | N=636 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1